
Clinical-stage AI neuroengineering platform
We're making every therapeutically valuable emotion available on demand in pharmaceutical form. Our Osmanthus platform is an ensemble of AI models that synthesize the world’s largest datasets of psychoactive pharmacology and phenomenology, quantitatively pinpointing the combination of neurotransmitter receptor activity that underlies various emotional as well as cognitive and perceptual states. Our lead program MSD-001 is designed to be rapid-acting and produce heightened emotional and cognitive flexibility without hallucinations. MSD-001 is currently in human trials, and will be the base ingredient for multiple drug combination "emotions in a bottle" such as empathy, awe, clarity, or beauty.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountNov 2024
Nov 2024
Feb 2022
Create a free account to see which investors have funded this company.
Create Free AccountNext-gen Medicare Advantage insurance plan with AI-forward medical group delivering quality and s...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...

Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...

OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...